JP2013107880A - Ｎ−チエニルベンズアミド誘導体 - Google Patents

Ｎ−チエニルベンズアミド誘導体 Download PDF

Info

Publication number
JP2013107880A
JP2013107880A JP2012236135A JP2012236135A JP2013107880A JP 2013107880 A JP2013107880 A JP 2013107880A JP 2012236135 A JP2012236135 A JP 2012236135A JP 2012236135 A JP2012236135 A JP 2012236135A JP 2013107880 A JP2013107880 A JP 2013107880A
Authority
JP
Japan
Prior art keywords
amino
methyl
ethyl
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012236135A
Other languages
English (en)
Japanese (ja)
Inventor
Michinori Miura
理憲 三浦
Shunichiro Yatani
俊一郎 八谷
Daisuke Kaga
大輔 加賀
Susumu Watanuki
晋 四月朔日
Takao Okuda
崇男 奥田
Makoto Oku
誠 奥
佳正 ▲今▼村
Yoshimasa Imamura
Jiro Fujiyasu
次郎 藤安
Daisuke Suzuki
大輔 鈴木
Hiroyuki Moritomo
博幸 森友
Koji Kato
浩二 加藤
Ippei Sato
一平 佐藤
Mai Isomura
真衣 磯村
Kazuo Kurosawa
一雄 黒澤
Tatsuya Yoshimitsu
龍哉 善光
Tatsuya Maruyama
龍也 丸山
Kosei Yoshihara
耕生 吉原
Kazuhiro Terai
和宏 寺居
Hiroshi Terada
央 寺田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to JP2012236135A priority Critical patent/JP2013107880A/ja
Publication of JP2013107880A publication Critical patent/JP2013107880A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C07D333/80—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2012236135A 2011-10-27 2012-10-25 Ｎ−チエニルベンズアミド誘導体 Pending JP2013107880A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012236135A JP2013107880A (ja) 2011-10-27 2012-10-25 Ｎ−チエニルベンズアミド誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011236533 2011-10-27
JP2011236533 2011-10-27
JP2012236135A JP2013107880A (ja) 2011-10-27 2012-10-25 Ｎ−チエニルベンズアミド誘導体

Publications (1)

Publication Number Publication Date
JP2013107880A true JP2013107880A (ja) 2013-06-06

Family

ID=48167891

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012236135A Pending JP2013107880A (ja) 2011-10-27 2012-10-25 Ｎ−チエニルベンズアミド誘導体
JP2013540835A Expired - Fee Related JP6020460B2 (ja) 2011-10-27 2012-10-25 アミノアルキル置換ｎ−チエニルベンズアミド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013540835A Expired - Fee Related JP6020460B2 (ja) 2011-10-27 2012-10-25 アミノアルキル置換ｎ−チエニルベンズアミド誘導体

Country Status (18)

Country Link
US (1) US9062032B2 (https=)
EP (1) EP2772490B1 (https=)
JP (2) JP2013107880A (https=)
KR (1) KR101941048B1 (https=)
CN (1) CN103906741B (https=)
AR (1) AR088563A1 (https=)
AU (1) AU2012329913A1 (https=)
BR (1) BR112014010169B1 (https=)
CA (1) CA2853688C (https=)
EA (1) EA023955B1 (https=)
ES (1) ES2585415T3 (https=)
IL (1) IL232230A0 (https=)
IN (1) IN2014CN03130A (https=)
MX (1) MX342521B (https=)
PH (1) PH12014500887A1 (https=)
PL (1) PL2772490T3 (https=)
TW (1) TW201323419A (https=)
WO (1) WO2013062065A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015064532A1 (ja) * 2013-10-30 2015-05-07 第一三共株式会社 モルホリン化合物
JP2015532295A (ja) * 2012-10-02 2015-11-09 エピセラピューティックス・エイ・ピー・エス ヒストン脱メチル化酵素の阻害剤
JP2019527734A (ja) * 2016-08-15 2019-10-03 イーライ リリー アンド カンパニー ＮａＰｉ−ＩＩｂ阻害剤として有用な縮合チオフェン誘導体

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2975030T (pt) 2013-03-13 2020-09-28 Chugai Pharmaceutical Co Ltd Derivado de di-hidropiridazina-3,5-diona
US9499553B2 (en) 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
TWI594975B (zh) * 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
PT3030568T (pt) 2013-08-08 2018-12-24 Galapagos Nv Tieno[2,3-c]piranos como moduladores de cftr
EP3126345A1 (en) * 2014-03-31 2017-02-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
WO2016026372A1 (zh) * 2014-08-22 2016-02-25 江苏恒瑞医药股份有限公司 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用
NZ729640A (en) * 2014-09-12 2022-04-29 Chugai Pharmaceutical Co Ltd Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
BR112017005694A2 (pt) 2014-09-26 2017-12-12 Daiichi Sankyo Co Ltd cristais de um sal, ou hidrato do mesmo, cristais de um trihidrato de sal dissódico, composição farmacêutica, uso dos cristais, e, método para prevenção ou tratamento de hiperfosfatemia.
CN105524053B (zh) * 2014-10-19 2020-06-05 广东东阳光药业有限公司 四氢苯并噻吩化合物
TW201700458A (zh) 2015-04-24 2017-01-01 第一三共股份有限公司 二羧酸化合物之製法
CN107082773B (zh) * 2016-02-16 2020-07-28 江苏恒瑞医药股份有限公司 一种肠2b型磷酸钠协同转运蛋白抑制剂的硫酸盐及其结晶形式
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
CN109422723B (zh) * 2017-08-25 2021-02-23 江苏恒瑞医药股份有限公司 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
KR20240018523A (ko) 2021-06-08 2024-02-13 추가이 세이야쿠 가부시키가이샤 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제
WO2023203254A2 (en) 2022-04-22 2023-10-26 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物
WO2024223617A1 (en) 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213048A1 (en) * 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
JP2007131532A (ja) 2001-09-28 2007-05-31 Kirin Brewery Co Ltd 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
AU2002354410A1 (en) * 2001-12-05 2003-06-17 Japan Tobacco Inc. Triazole compound and medicinal use thereof
WO2004085382A1 (ja) 2003-03-27 2004-10-07 Kirin Beer Kabushiki Kaisha 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
AU2005279845A1 (en) * 2004-08-30 2006-03-09 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Inhibition of viruses using RNase H inhibitors
JP2008517061A (ja) 2004-10-20 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 抗腫瘍剤としての化合物及びそれらの使用
AU2009203549B2 (en) * 2008-01-08 2013-03-07 Purdue Pharma L.P. Proline Analogs as ligands for cannabinoid receptors for the treatment of pain
PL2565190T3 (pl) 2010-04-28 2015-10-30 Astellas Pharma Inc Związek tetrahydrobenzotiofenowy
JP5827327B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5823514B2 (ja) 2010-07-07 2015-11-25 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012006477A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590655B1 (en) 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532295A (ja) * 2012-10-02 2015-11-09 エピセラピューティックス・エイ・ピー・エス ヒストン脱メチル化酵素の阻害剤
WO2015064532A1 (ja) * 2013-10-30 2015-05-07 第一三共株式会社 モルホリン化合物
JP2019527734A (ja) * 2016-08-15 2019-10-03 イーライ リリー アンド カンパニー ＮａＰｉ−ＩＩｂ阻害剤として有用な縮合チオフェン誘導体

Also Published As

Publication number Publication date
CA2853688C (en) 2018-06-12
EP2772490A4 (en) 2015-01-21
PL2772490T3 (pl) 2016-11-30
EP2772490A1 (en) 2014-09-03
MX342521B (es) 2016-10-03
WO2013062065A1 (ja) 2013-05-02
CA2853688A1 (en) 2013-05-02
CN103906741B (zh) 2016-01-20
TW201323419A (zh) 2013-06-16
CN103906741A (zh) 2014-07-02
EA201490875A1 (ru) 2014-09-30
BR112014010169B1 (pt) 2021-12-07
JP6020460B2 (ja) 2016-11-02
EA023955B1 (ru) 2016-07-29
BR112014010169A2 (pt) 2017-04-25
KR20140096322A (ko) 2014-08-05
PH12014500887A1 (en) 2019-06-03
EP2772490B1 (en) 2016-04-06
IL232230A0 (en) 2014-06-30
MX2014005090A (es) 2015-02-12
AU2012329913A1 (en) 2014-05-22
US20150031727A1 (en) 2015-01-29
ES2585415T3 (es) 2016-10-05
JPWO2013062065A1 (ja) 2015-04-02
IN2014CN03130A (https=) 2015-07-03
KR101941048B1 (ko) 2019-01-22
US9062032B2 (en) 2015-06-23
AR088563A1 (es) 2014-06-18

Similar Documents

Publication Publication Date Title
JP6020460B2 (ja) アミノアルキル置換ｎ−チエニルベンズアミド誘導体
JP5408434B2 (ja) アミド化合物
KR101721025B1 (ko) 테트라하이드로벤조티오펜 화합물
JP6056872B2 (ja) イミダゾピリジン化合物
CN102300863B (zh) 具有乙基和乙烯基连接体的异*唑/邻-吡啶衍生物
US8802679B2 (en) Glycine compound
CA2848561C (en) Guanidinobenzoic acid compound
JP5781611B2 (ja) Ｌｒｒｋ２キナーゼ阻害剤としての２−（ベンジルオキシ）ベンズアミド類
KR20140040774A (ko) 이미다조피리딘 화합물
JP2013177318A (ja) ジヒドロピリミジノン誘導体およびその医薬用途
JP2025081449A (ja) オキサジアゾール誘導体
JPH09509957A (ja) 免疫調節剤としてのキノリン誘導体
US20250346569A1 (en) New derivatives for treating trpm3 mediated disorders
JP7653399B2 (ja) オキサジアゾール誘導体を含有する医薬組成物
TW202310830A (zh) 用於治療疾病之β-內醯胺衍生物
CN118019738A (zh) 作为sting拮抗剂的小分子脲衍生物
HK1203486A1 (en) Benzoheterocyclic compounds and use thereof
WO2012115066A1 (ja) グリシントランスポーター阻害物質

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140918